Overview of tyrosine kinase inhibitors in clinical breast cancer.
about
Breast cancer chemoprevention: old and new approachesNanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancerCharacterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging.A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancersEGFR associated expression profiles vary with breast tumor subtypeGemcitabine Conjugated Chitosan and Double Antibodies (Abc-GC-Gemcitabine Nanoparticles) Enhanced Cytoplasmic Uptake of Gemcitabine and Inhibit Proliferation and Metastasis In Human SW1990 Pancreatic Cancer Cells.Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment.Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapyZD6474 coerces breast cancer for an apoptotic journeyHigh-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy.Standard of care and promising new agents for triple negative metastatic breast cancerOncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancerManagement options in triple-negative breast cancerMicrobead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cellsRegulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer.Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidenceTransphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study.Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer.EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy.Anti-epidermal growth factor receptor strategies for advanced breast cancer.The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer.Lapatinib: new opportunities for management of breast cancer.Triple-negative breast cancer: present challenges and new perspectives.Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors.Integrating breast cancer genetics into clinical practice.Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer.Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling.Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain.Role of bacteria in carcinogenesis, with special reference to carcinoma of the gallbladder.Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.Triple-negative breast cancer and its association with obesity.Structure-activity studies of peptidomimetics based on kinase-inhibitory region of suppressors of cytokine signaling 1.Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance.
P2860
Q27693259-0C1F536C-65DB-4F17-A46C-FB5C76D9FB31Q28480835-4338EB19-B64E-4A89-B1BB-50CD8126052BQ30891321-D45D3742-D6E1-4AB5-A067-985D6A78906BQ33289245-442726E5-E60D-49EC-919F-2FD3E8D5DC99Q33292502-A705AE1E-88A3-4D41-87BF-279557833536Q33553830-4737C04B-CF54-46C4-8121-B844ECC5DB64Q33705431-FED5DE87-F8C2-4CFF-B352-653199A6C208Q34023653-A591AAD1-10AA-46FC-B29C-07EF57BF57B0Q34440490-6AA66DA6-4512-4C64-B79E-ED5A488BDC07Q34549892-C8297642-1730-45E8-8C63-88834BDAE252Q34774884-7A8871AD-D0E9-44E1-99AB-B8FB2577AFADQ35007438-1FE8F225-2D39-46F9-A3C0-775279596492Q35155460-D1AFB0DF-5930-4B29-AF34-27FF4A37CE23Q35379924-B8998D03-C3AB-4068-8E52-07E4F02C8D82Q35916537-A55D82CA-1DC9-41E5-B247-3D3E184FC6CDQ36250585-3912BC04-35AE-4A9C-B08F-B3D9ED992C6CQ36458755-58BAB6A0-1E8F-4E50-8271-38CF07E11429Q37006174-674221B0-A266-4514-9BAD-6647AE119DDDQ37030174-12E7011D-D962-451C-8D87-0833E91E05D5Q37158137-2BD38FD8-964F-4409-8574-840997956F2CQ37206247-3871FC72-ACCB-43A4-A79A-79EDBF33995CQ37293327-8CC75993-9391-45C4-A4D2-0FCE29120286Q37304764-5C41C9DE-E82D-4A46-8AEB-71B549BC3009Q37355729-322C6465-3D4E-445B-8C72-B81254DE970BQ37764168-E456C584-4C3E-49A9-884C-7567370244D8Q37863629-6CEF3FAB-EC31-48AD-A1E3-2BBFB606F6CEQ37968654-D80878CD-8070-441D-82EE-9F0640AF2110Q38303667-90626428-4D4A-4475-AA90-8DBF8D2BFC72Q38885404-BFAE4E9E-A733-4FCF-BC63-B2491192159EQ39709408-CFF5EE55-C470-4B5C-ACD6-B3746EC1BD0BQ42350897-03CDE12A-F590-43B0-8EBD-0F0E10576F69Q42579657-AC45E7B2-C4EE-4683-ACD2-1AFB91A7DBAAQ47099775-57776B17-80BA-4C8B-8150-DCCE15117251Q47386577-D0353D6D-72A9-4AEF-B69D-E17BFDF7028AQ54610139-1C79E08D-FB9E-43C0-A4DB-F95BDA55CEF8
P2860
Overview of tyrosine kinase inhibitors in clinical breast cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Overview of tyrosine kinase inhibitors in clinical breast cancer.
@ast
Overview of tyrosine kinase inhibitors in clinical breast cancer.
@en
type
label
Overview of tyrosine kinase inhibitors in clinical breast cancer.
@ast
Overview of tyrosine kinase inhibitors in clinical breast cancer.
@en
prefLabel
Overview of tyrosine kinase inhibitors in clinical breast cancer.
@ast
Overview of tyrosine kinase inhibitors in clinical breast cancer.
@en
P2093
P356
P1476
Overview of tyrosine kinase inhibitors in clinical breast cancer
@en
P2093
E Gutteridge
J F R Robertson
R I Nicholson
P304
P356
10.1677/ERC.1.01059
P478
12 Suppl 1
P50
P577
2005-07-01T00:00:00Z